Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$261.3MBeat by $10.5M
EPS$1.28Beat by $0.32
Revenue estimate$250.8M
EPS estimate$0.96
“Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders. The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications.”
Jeffrey M. Dayno

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$274.5M
EPS estimate$1.11

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$2.46B+33.3%
Enterprise value$2.03B+38.2%
P/E16.9×+6.7×
P/S2.7×+0.3×

FAQ

When did Harmony Biosciences Holdings, Inc. report Q2 2026 earnings?
Harmony Biosciences Holdings, Inc. (HRMY) reported Q2 2026 earnings on August 4, 2026 before market open.
What were Harmony Biosciences Holdings, Inc.'s Q2 2026 revenue and EPS?
Harmony Biosciences Holdings, Inc. reported revenue of $261.3M and eps of $1.28 for Q2 2026.
Did Harmony Biosciences Holdings, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $250.8M by $10.5M. EPS beat the consensus estimate of $0.96 by $0.32.
How did Harmony Biosciences Holdings, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 30.3% from $200.5M a year earlier and eps grew 88.2% from $0.68.
Where can I find Harmony Biosciences Holdings, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-090086) and the 10-Q periodic report (0001104659-26-090090) directly on SEC EDGAR. The filing index links above go to sec.gov.